Literature DB >> 16738191

Classification and natural history of the idiopathic interstitial pneumonias.

Dong Soon Kim1, Harold R Collard, Talmadge E King.   

Abstract

In the American Thoracic Society/European Respiratory Society consensus classification, idiopathic interstitial pneumonias are classified into seven clinicopathologic entities. The classification is largely based on histopathology, but depends on the close interaction of clinician, radiologist, and pathologist. An accurate diagnosis can be very difficult, especially when deciding between idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia; better diagnostic markers are needed. The prognosis of idiopathic pulmonary fibrosis is very poor, with median survival of 2-4 yr after the diagnosis, yet the course of individual patients is highly variable. Predicting prognosis in the individual patient is challenging but various clinical and radiologic variables have been identified. According to several recent clinical trials, the natural history of this disease may involve periods of relative stability punctuated by acute exacerbations of disease that result in substantial morbidity or death. Nonspecific interstitial pneumonia is characterized by a distinct histopathologic appearance and a better prognosis than idiopathic pulmonary fibrosis. However, there is still confusion and controversy over the relationship between idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16738191      PMCID: PMC2658683          DOI: 10.1513/pats.200601-005TK

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  60 in total

1.  Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF.

Authors:  S Nagai; M Kitaichi; K Hamada; T Nagao; Y Hoshino; H Miki; T Izumi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  1999-09       Impact factor: 0.670

Review 2.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

3.  Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis.

Authors:  G W Hunninghake; M B Zimmerman; D A Schwartz; T E King; J Lynch; R Hegele; J Waldron; T Colby; N Müller; D Lynch; J Galvin; B Gross; J Hogg; G Toews; R Helmers; J A Cooper; R Baughman; C Strange; M Millard
Journal:  Am J Respir Crit Care Med       Date:  2001-07-15       Impact factor: 21.405

4.  Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia.

Authors:  W D Travis; K Matsui; J Moss; V J Ferrans
Journal:  Am J Surg Pathol       Date:  2000-01       Impact factor: 6.394

5.  Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features.

Authors:  D S Kim; J H Park; B K Park; J S Lee; A G Nicholson; T Colby
Journal:  Eur Respir J       Date:  2006-01       Impact factor: 16.671

6.  The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study.

Authors:  G Raghu; Y N Mageto; D Lockhart; R A Schmidt; D E Wood; J D Godwin
Journal:  Chest       Date:  1999-11       Impact factor: 9.410

Review 7.  Acute interstitial pneumonitis. Case series and review of the literature.

Authors:  J S Vourlekis; K K Brown; C D Cool; D A Young; R M Cherniack; T E King; M I Schwarz
Journal:  Medicine (Baltimore)       Date:  2000-11       Impact factor: 1.889

8.  The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

Authors:  A G Nicholson; T V Colby; R M du Bois; D M Hansell; A U Wells
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

Review 9.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

10.  Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?

Authors:  Kevin R Flaherty; Talmadge E King; Ganesh Raghu; Joseph P Lynch; Thomas V Colby; William D Travis; Barry H Gross; Ella A Kazerooni; Galen B Toews; Qi Long; Susan Murray; Vibha N Lama; Steven E Gay; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2004-07-15       Impact factor: 21.405

View more
  126 in total

1.  Lung transplant for interstitial lung disease: outcomes for single versus bilateral lung transplantation.

Authors:  Nilto C De Oliveira; Satoru Osaki; James Maloney; Richard D Cornwell; Keith C Meyer
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-12-16

2.  Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Carolyn S Calfee; Paul J Wolters; Jin Woo Song; Sang-Bum Hong; Sandra Brady; Akitoshi Ishizaka; Kirk D Jones; Talmadge E King; Michael A Matthay; Dong Soon Kim
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-04-23       Impact factor: 5.464

Review 3.  [Idiopathic interstitial pneumonias: from classification to diagnostic work-up].

Authors:  C Müller-Mang; L Stiebellehner; K Schmid; A Bankier
Journal:  Radiologe       Date:  2007-05       Impact factor: 0.635

Review 4.  [Therapy for idiopathic interstitial pneumonias: steroids--and what else?].

Authors:  A Prasse; J Müller-Quernheim
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

Review 5.  Acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-06-21       Impact factor: 21.405

6.  Dual-time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia.

Authors:  Yukihiro Umeda; Yoshiki Demura; Takeshi Ishizaki; Shingo Ameshima; Isamu Miyamori; Yuji Saito; Tatsuro Tsuchida; Yasuhisa Fujibayashi; Hidehiko Okazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-27       Impact factor: 9.236

Review 7.  Antioxidants as potential therapeutics for lung fibrosis.

Authors:  Brian J Day
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

8.  Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Authors:  Lynne A Murray; Huilan Zhang; Sameer R Oak; Ana Lucia Coelho; Athula Herath; Kevin R Flaherty; Joyce Lee; Matt Bell; Darryl A Knight; Fernando J Martinez; Matthew A Sleeman; Erica L Herzog; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

Review 9.  Extracellular superoxide dismutase in pulmonary fibrosis.

Authors:  Fei Gao; Vuokko L Kinnula; Marjukka Myllärniemi; Tim D Oury
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

Review 10.  High-resolution computed tomography in the diagnosis and follow-up of idiopathic pulmonary fibrosis.

Authors:  N Sverzellati; M De Filippo; T Bartalena; S Piciucchi; M Zompatori
Journal:  Radiol Med       Date:  2010-01-15       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.